Mar 29, 2023 8:00 am EDT Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Mar 16, 2023 4:05 pm EDT Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update
Mar 16, 2023 4:05 pm EDT Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update
Mar 8, 2023 8:00 am EST Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Mar 3, 2023 8:00 am EST Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Mar 2, 2023 8:00 am EST Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
Feb 7, 2023 8:00 am EST Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Feb 2, 2023 8:00 am EST Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference